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Objectives This study sought to compare the efﬁcacy and safety results after coronary implantation
of a combined sirolimus-eluting CD34 antibody coated Combo stent (OrbusNeich Medical, Ft. Lau-
derdale, Florida) with the paclitaxel-eluting Taxus Liberté stent (PES) (Boston Scientiﬁc, Natick, Mas-
sachusetts). This report summarizes the ﬁrst-in-man randomized, controlled multicenter REMEDEE
trial (Randomized study to Evaluate the safety and effectiveness of an abluMinal sirolimus coatED
bio-Engineered StEnt) angiographic, intravascular ultrasound, and clinical results up to 12 months.
Background Drug-eluting stents have limited restenosis and reintervention but are complicated by
especially late and very late stent thrombosis and accelerated neoatherosclerosis. Alternative or ad-
junct technologies should address these limitations.
Methods One hundred eighty-three patients with de novo native coronary artery stenoses were
randomized 2:1 to Combo stent or PES implantation. The primary endpoint is the angiographic in-
stent late lumen loss at 9 months, which was tested for noninferiority between the 2 stent groups.
Secondary endpoints include the occurrence of major adverse cardiac events.
Results The Combo stent was found to be noninferior to the PES in 9-month angiographic in-stent
late lumen loss with 0.39  0.45 mm versus 0.44  0.56 mm (pnoninferiority  0.0012). At 12 months,
the occurrence of major adverse cardiac events was 8.9% in the Combo group and 10.2% in the PES
group (p  0.80) with no difference in mortality, occurrence of myocardial infarction, or target
lesion revascularization. No stent thrombosis was reported in either group.
Conclusions In the REMEDEE trial the Combo stent has shown to be effective by meeting the primary
noninferiority angiographic endpoint and safe, with an overall low rate of clinical events in both stent
groups, including no stent thrombosis up to 12 months. (J Am Coll Cardiol Intv 2013;6:334–43) © 2013
by the American College of Cardiology Foundation
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335Drug-eluting stents (DES) are associated with a significant
reduction in neointimal formation compared with bare-
metal stents (BMS), resulting in significant reductions in
restenosis and reintervention rates. In the inaugural
RAVEL trial (A Randomized Study With the Sirolimus
Coated Modified BX Velocity Balloon-Expandable Stent in
the Treatment of Patients With de Novo Native Coronary
Artery Lesions) (1) with the sirolimus-eluting stent (SES),
angiographic late lumen loss (LLL) was not measurable by
angiography, with an accompanying absence of restenosis.
Furthermore, it was observed and cautioned that DES are
complex and that the long-term outcomes with these devices
would depend on the response to 3 components: the stent, the
oating, and the drug. These impressive results have not been as
urable as initially hoped, being tempered especially by the
ngoing occurrence of late and very late stent thrombosis (ST) (2),
despite the prolonged use of dual antiplatelet therapy (DAPT)
and additionally the development of in-stent neo-atherosclerosis.
These observations led to the development of second-
generation DES that sought to improve the first generation
by provision of thinner and absorbable polymer layers,
thinner stent struts, alternative drug compounds, and lower
doses of drugs. These modifications should produce more
biologically compatible stents that would limit the response to
stent injury through the healing process. These advancements
resulted in lower risks of ST and target lesion revascularization
(TLR) (3) rates.
Nevertheless, ST, restenosis, and in-stent neo-
atherosclerosis remain an issue with contemporary DES.
Therefore, further improvements should address early and
predictive healing with neointimal stent strut coverage,
allowing a significantly shorter duration of DAPT without
losing efficacy with respect to LLL, restenosis, and the need
for reintervention.
The immobilization of CD34 antibodies directed toward
circulating endothelial progenitor cells (EPCs) applied to
intravascular stents has been shown in a human ex vivo
shunt model to increase the rate of cellular coverage, the
expression of endothelial phenotype markers in the captured
cells, and modulation of ST (4). When the CD34 antibody
technology was applied to commercially available SES, it
was shown to promote vascular healing and endothelializa-
tion (5). This has led to the development of a specifically
engineered device, the Combo Bioengineered Sirolimus-
Eluting Stent (OrbusNeich Medical, Ft. Lauderdale, Flor-
ida), which combines sirolimus elution from an abluminal
biodegradable polymer matrix along with a covalently
bound CD34 antibody layer in a combination device de-
consultant to Boston Scientific and Medtronic. Dr. Maehara has received speaker’s
fees from St. Jude Medical; and research grant support from Boston Scientific. All
other authors have reported that they have no relationships relevant to the contents of
this paper to disclose.Manuscript received October 18, 2012; accepted October 26, 2012.signed for control of neointimal proliferation as well as to
promote vessel healing with accelerated stent strut tissue
coverage (6) (Fig. 1).
Methods
The REMEDEE (Randomized study to Evaluate the safety
and effectiveness of an abluMinal sirolimus coatED bio-
Engineered StEnt) trial was undertaken to demonstrate the
efficacy and safety of the Combo compared with the commercially
available paclitaxel-eluting Taxus
Liberté stent (PES) (Boston Scien-
tific, Natick, Massachusetts) in the
treatment of single de novo native
coronary artery lesions.
Study management. The RE-
MEDEE trial was conducted as
a first-in-man multinational
trial. The study sponsor pro-
vided financial support and the
Combo stent study devices but
otherwise was not directly in-
volved with the study processes.
An independent clinical research
organization (Cardiovascular
Research Foundation, New
York, New York) had study re-
sponsibility for data collection;
safety monitoring; angiographic,
intravascular ultrasound, and
electrocardiography core lab as-
sessments; adjudication of ad-
verse events by a Clinical Events
Committee; data analysis; and
independent regional site moni-
toring. The study was con-
ducted in accordance with the
Declaration of Helsinki, and
the trial protocol and patient
informed consent were re-
viewed and approved by all
sites’ institutional ethics com-
mittees and the respective local
regulatory agencies.
Patient population. Patients eligible to participate in the
tudy were 18 and 80 years of age, presenting with
yocardial ischemia due to a50% stenosed single de novo
esion20 mm in length in a native coronary artery ranging
n diameter from 2.5 to 3.5 mm. Patients had to be
acceptable candidates for bypass surgery, should be amenable to
long-term DAPT for a minimum of 6 months, and needed
to be willing to comply with the specified follow-up evalu-
ations. All patients were informed of the nature of the study,
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
DS  diameter stenosis
EPC  endothelial progenitor
cell
HAMA  human anti-murine
antibody
IQR  interquartile range
IVUS  intravascular
ultrasound
LLL  late lumen loss
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
QCA  quantitative coronary
angiography
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
VH  virtual histologyand written informed consent was obtained.
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336Study protocol and randomization. Patients presenting with
symptoms of myocardial ischemia were evaluated with the
inclusion/exclusion criteria (Online Appendix) for their
clinical appropriateness and their angiographic suitability.
Baseline angiography of the target vessel was performed in
at least 2 orthogonal views according to the angiographic
core laboratory guidelines. Pre-dilation of the target lesion
was performed per study stent labeling at the discretion of
the operator but was mandatory in the setting of calcified
lesions. Randomization was assigned with a sealed envelope
method in an open-label 2:1 ratio to treatment with a
Combo or PES.
Pre-procedural antiplatelet medication included: clopi-
dogrel loading dose of 600 mg administered 0 to 24 h
before the procedure or, for those patients already receiv-
ing chronic clopidogrel therapy of 75 mg (5 days), a
loading dose of 300 mg was given; if the subject was
allergic to clopidogrel, ticlopidine (500 mg) was admin-
istered 6 h before the procedure; all patients received a
loading dose of aspirin (300 or 325 mg or dose per
standard hospital practice) at least 2 h before the proce-
dure. Subjects received appropriate peri-procedural anti-
coagulation medications during the stenting procedure
according to the local site practice.
Before stent implantation, coronary angiography of the
target lesion was recorded in 2 orthogonal views after
vasodilation with nitroglycerine. Stents were sized after a
stent/artery ratio of 1.1:1. It was recommended that a
minimum of 1.5 mm of nondiseased vessel segment on
Figure 1. Combo Dual Therapy Stent
Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida).either side of the lesion should be covered by the stent. Ifnecessary, post-dilation of the deployed stents was recom-
mended with a noncompliant shorter balloon within the
boundaries of the implanted stent. Bail-out stenting was
allowed to treat major flow-limiting dissections, with a
study stent of the same type as the randomization stent of
the subject in an appropriate size.
“Device success” was defined as an achievement of a final
in-stent residual diameter stenosis (DS) of 50% (by
quantitative coronary angiography [QCA]), with the as-
signed device only and without device malfunction. “Lesion
success” was defined as an achievement of a final in-stent
residual DS of 50% (by QCA) with any percutaneous
method, whereas “procedure success” was quoted as an
achievement of a final in-stent DS of50% (by QCA) with
the assigned device and with any adjunctive devices, without
the occurrence of cardiac death, Q-wave or non–Q-wave
myocardial infarction (MI), or repeat vascularization of the
target lesion during the hospital stay.
Post-procedure angiography of the target vessel was
performed in the same 2 orthogonal views showing the
target lesion, which were repeated during 9-month
follow-up angiography.
Six sites were prospectively designated to collect baseline
and 9-month intravascular ultrasound (IVUS) with either a
20-MHz imaging catheter (n  23) (Eagle Eye Gold,
olcano, Rancho Cordova, California) or a mechanical
otating element 40-MHz transducer (n  43) (Atlantis,
oston Scientific) both by automated pullback at 0.5 mm/s.
Post-procedure, all subjects were treated for at least 6
onths up to 12 months with clopidogrel (75 mg/day).
spirin was prescribed (minimum of 75 mg/day and up to
62 mg/day or dose per local site practice) indefinitely as
olerated per the percutaneous coronary intervention (PCI)
reatment guidelines (7,8).
Clinical follow-up. The assessment of safety and effectiveness
as evaluated during telephone contacts or office visits at the
ollowing time points: in-hospital 30 7 days; 9 months 30
ays; and 1 year  30 days. Continuing clinical follow-up is
lanned at 2, 3, 4, and 5 years  60 days.
Study endpoint deﬁnitions. The primary study endpoint
was defined as angiographic in-stent LLL at 9 months.
Secondary efficacy endpoints included: device, lesion, and
procedural success; clinically (ischemia)-driven TLR; clini-
cally (ischemia)-driven target vessel revascularization; clin-
ically (ischemia)-driven target vessel failure; clinically
driven-target lesion failure; in-stent, and in-segment angio-
graphic binary restenosis; in-stent and in-segment angio-
graphic minimum lumen diameter; and neointimal hyper-
plasia volume and percentage in-stent volume obstruction
by IVUS and tissue composition of the vessel wall, especially
of the intra-stent tissue with backscatter analysis of radio-
frequency signals (IVUS-virtual histology [VH]) at 9
months (9,10). Secondary safety endpoints included the
occurrence of: all-cause and cardiac mortality; MI; major
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337adverse cardiac events; and ST. Vascular complications were
reported from index procedure through hospital discharge.
Each patient was assessed for a human anti-murine anti-
body (HAMA) response at 30 days and 9 months.
Adjudication of study endpoints. All angiographic, IVUS-
based, and clinical (including ST per the Academic Re-
search Consortium [ARC] [11] definitions) endpoints were
measured and assessed by the Angiographic Core Labora-
tory (Cardiovascular Research Foundation, New York) and
adjudicated by the Clinical Event Committee, which re-
ported to the Data Safety Monitoring Board.
Statistical analysis. The primary endpoint was an efficacy
endpoint of noninferiority in 9-month angiographic in-
stent LLL between the Combo and PES. It was assumed
that the in-stent LLL at 9 months for the PES would be
0.40 and 0.30 mm for Combo with similar SDs of 0.53 mm
(12). A noninferiority margin of 0.20 mm was chosen. With
a statistical power of 90%, an -error of 0.05, a 2:1
randomization, and an anticipated loss to follow-up of 20%,
a sample size determination found that 120 patients should
be randomized to the Combo and 60 to the TAXUS arm.
An intention-to-treat analysis was performed for the
primary endpoint with the noninferiority t test. Per study
protocol, if the test for noninferiority was successful, then a
test for superiority was to be performed. All angiographic
secondary endpoints were evaluated in the full analysis set
with descriptive statistics. All clinical secondary endpoints
were evaluated in the intention-to-treat population without
pre-defined hypothesis testing. The secondary endpoints
were summarized with the mean, median, SD, minimum,
maximum, and sample size for each treatment group,
including 2-sided 95% confidence intervals (CIs) of the
mean difference between the treatment groups for continu-
ous variables; frequencies, percentages, and 2-sided exact
95% CIs for binary endpoints; or time-to-event Kaplan-
Meier analysis, as appropriate, for clinical endpoints. A
p value of 0.05 was considered statistically significant.
Results
Between November 2009 and August 2010, a total of 183
patients were enrolled at 17 investigative sites in Australia,
Europe, Brazil, and Asia-Pacific, with 124 in the Combo
group and 59 in the PES group.
Baseline characteristics. The baseline key demographic
data, medical history, pre-procedural cardiac status, and
baseline lesion characteristics were well-matched between
the study groups (Tables 1 and 2). A relatively high
proportion of the subjects (33.1% and 37.3%, respec-
tively) were diabetic. No significant differences were seen
in any of these baseline parameters between the treatment
groups.
Procedural results. The baseline device and procedural
characteristics are summarized in Table 3. The proceduresuccess was 96.8% in the Combo group and 98.3% in the
PES group (p 1.00). There were no significant differences
in any of these procedural parameters between the treatment
groups.
Primary endpoint. In the Combo group, in-stent LLL was
.39  0.45 mm, which was noninferior to the in-stent
LL of 0.44  0.56 mm in the PES group (pnoninferiority 
0.0012). This difference in in-stent LLL of 0.05 mm in
favor of the Combo stent was not statistically significant
(psuperiority  0.5514). The distribution of in-stent LLL in
the PES group showed a bimodal appearance resulting in a
larger SD, compared with the Combo group (Fig. 2). With
regard to the non-normal nature of the in-stent LLL
distributions, the nonparametric Mann–Whitney test of the
medians was performed with the same margin of 0.20 mm
as before. The result of this test confirmed that the 9-month
Table 1. Baseline Clinical Characteristics
Combo
(n  124)
TAXUS
(n  59) p Value
Age (yrs) 64.20  9.48 64.05  10.49 0.92
Men 89 (71.8%) 42 (71.2%) 0.93
Smoking/tobacco usage 71 (57.3%) 28 (47.5%) 0.21
Current smoker 26 (21.0%) 10 (16.9%) 0.52
Diabetes mellitus 41 (33.1%) 22 (37.3%) 0.57
Insulin-dependent 9 (7.3%) 7 (11.9%) 0.30
History of hypertension 100 (80.6%) 45 (76.3%) 0.50
History of hyperlipidemia 102 (82.3%) 43 (72.9%) 0.14
Left ventricular ejection
fraction (%)
63.87  11.93 (119) 63.33  11.59 (59) 0.77
Premature cardiovascular
disease in 1st-
degree relative
36 (29.0%) 23 (39.0%)
Previous congestive
heart failure
17 (13.7%) 6 (10.2%) 0.50
Previous MI 31 (25.0%) 16 (27.1%) 0.76
Previous PCI 29 (23.4%) 12 (20.3%) 0.64
Previous CABG 4 (3.2%) 2 (3.4%) 1.00
History of renal
insufﬁciency
8 (6.5%) 1 (1.7%) 0.28
Angina status
Silent ischemia 13 (10.5%) 6 (10.2%) 0.95
Stable angina 91 (73.4%) 43 (72.9%) 0.94
CCS I 13 (10.5%) 10 (16.9%) 0.22
CCS II 60 (48.4%) 29 (49.2%) 0.92
CCS III 15 (12.1%) 4 (6.8%) 0.27
CCS IV 3 (2.4%) 0 (0.0%) 0.55
Unstable angina 20 (16.1%) 10 (16.9%) 0.89
Braunwald I 6 (4.8%) 2 (3.4%) 1.00
Braunwald II 8 (6.5%) 2 (3.4%) 0.50
Braunwald III 6 (4.8%) 6 (10.2%) 0.21
Values aremean SD or n (%). Combo stent (OrbusNeichMedical, Ft. Lauderdale, Florida); Taxus
Liberté stent (PES) (Boston Scientific, Natick, Massachusetts).
CABG  coronary bypass surgery; CCS  Canadian Cardiovascular Society; MI  myocardial
infarction; PCI percutaneous coronary intervention.in-stent late loss with the Combo stent is noninferior to the
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338TAXUS Liberté stent (Combo: median  0.29 mm, inter-
quartile range [IQR: 0.485 mm; TAXUS: median 0.29 mm,
IQR: 0.445 mm; 95% CI for the difference between the
medians: 0.120 to 0.120, pnoninferiority  0.002).
Secondary angiographic and IVUS endpoints. At the
-month angiographic follow-up, all results of the angio-
raphic and IVUS measurements were comparable between
he groups (Table 4). The 9-month angiographic group
onsisted of 109 from the Combo group and 52 from the
ES group. The Combo stent showed a numerically lower
ccurrence of angiographic binary restenosis and a trend
Table 2. Baseline Lesion Characteristics
Combo
(n  124)
TAXUS
(n  59) p Value
Target lesion type,
de novo
124 (100.0%) 59 (100.0%) N/A
Target lesion vessel
LAD 54 (43.5%) 32 (54.2%) 0.18
RCA 31 (25.0%) 10 (16.9%) 0.22
Circumﬂex 39 (31.5%) 17 (28.8%) 0.72
Lesion location
Ostial 1 (0.8%) 1 (1.7%) 0.54
Proximal 44 (35.5%) 23 (39.0%) 0.65
Mid 67 (54.0%) 28 (47.5%) 0.41
Distal 12 (9.7%) 7 (11.9%) 0.65
Lesion length (mm) 13.69  5.07 14.64  4.41 0.22
(min, max) (5.08, 45.57) (5.25, 24.83) N/A
Eccentric 4 (3.2%) 5 (8.5%) 0.15
Angulation 45° 12 (9.7%) 4 (6.8%) 0.52
Thrombus 0 (0.0%) 0 (0.0%) N/A
Tortuosity
None 119 (96.0%) 57 (96.6%) 1.00
Moderate 4 (3.2%) 2 (3.4%) 1.00
Severe 1 (0.8%) 0 (0.0%) 1.00
Calciﬁcation
None or mild 97 (78.2%) 51 (86.4%) 0.19
Moderate 26 (21.0%) 8 (13.6%) 0.23
Severe 1 (0.8%) 0 (0.0%) 1.00
TIMI score
TIMI 0 0 (0.0%) 0 (0.0%) N/A
TIMI 1 1 (0.8%) 1 (1.7%) 0.54
TIMI 2 5 (4.0%) 2 (3.4%) 1.00
TIMI 3 118 (95.2%) 56 (94.9%) 1.00
ACC/AHA lesion class
A 14 (11.3%) 12 (20.3%) 0.10
B1 28 (22.6%) 11 (18.6%) 0.54
B2 70 (56.5%) 30 (50.8%) 0.48
C 12 (9.7%) 6 (10.2%) 0.92
Pre-procedure RVD (mm) 2.77  0.42 2.85  0.34 0.18
Values are n (%) or mean SD.
ACCAmericanCollegeof Cardiology; AHAAmericanHeart Association; LAD left anterior
descending artery; RCA right coronary artery; RVD reference vessel diameter; TIMI Throm-
bolysis In Myocardial Infarction.oward a reduced in-segment LLL in comparison with theES. In addition to the 2-sample t test of the in-segment
LL (Table 3), the nonparametric Mann–Whitney test of
he medians of the in-segment LLL was performed with the
ollowing result: Combo: median  0.16 mm, IQR: 0.445
m; TAXUS: median  0.31 mm, IQR: 0.680 mm; 95%
I for the difference between the medians: 0.291 to
.045, psuperiority  0.127.
Baseline IVUS was performed in a subgroup of 66
patients (45 Combo and 21 Taxus). The IVUS follow-up at
9 months consisted of 35 from the Combo group and 17
from the PES group. IVUS revealed a numerically lower
neointimal hyperplasia volume of 21.5  21.7 mm3 versus
5.9  18.7 mm3 (p  0.4955) for Combo compared with
PES. The in-stent volume obstruction was 15.24  14.22%
versus 14.59 8.38% (p 0.8432). IVUS-VH comparison of
Combo with PES found a significantly less necrotic core area
at maximum site on neointimal hyperplasia of 0.25 mm2 versus
0.46 mm2 (p 0.04) and a less confluent necrotic core of 10%
versus 80% (p  0.02), as illustrated in Figure 3.
Secondary clinical endpoints. The adjudicated clinical end-
points and associated Kaplan-Meier estimates for event rates at
30 days and 12 months are summarized in Table 5. Very low
event rates were reported in all categories for both groups, with
no significant differences in any of the categories. Two deaths
were reported in the Combo group. One patient first received
a nonstudy device in the right coronary artery (nontarget vessel)
and then a Combo in the left circumflex coronary artery during
the index procedure. This patient underwent 9-month
follow-up angiography, revealing both stents patent. The site
coordinator learned the patient had died on day 324 post-index
PCI while scheduling the 1-year follow-up. The site reported
that the patient was receiving DAPT at the time of death. The
critical event committee has adjudicated this as a cardiac death.
The other patient developed a sub-arachnoidal hemorrhage
while taking DAPT, leading to a fatal outcome. This case was
adjudicated by the Clinical Events Committee as a noncardiac
death. All incidences of MI in both groups were cases of
peri-procedural non–Q-wave MI associated with the index
procedure. No ARC definite or probable ST occurred in either
group during the 12-month follow-up period.
HAMA plasma level response. At baseline, 4 subjects were
ound to have a detectable level of HAMA, but coincidentally
one of these were randomized to the Combo arm—all were in
he PES cohort. At both 30 day and 9-month follow-up, none
f the subjects receiving the Combo device showed a detectable
evel, whereas 3 of the subjects receiving the PES had detect-
ble levels of HAMA at both follow-up time points.
iscussion
Angiographic results. In the REMEDEE trial, the Combo
stent was found to be noninferior to the PES with respect to
9-month angiographic in-stent LLL and thereby met its
primary endpoint. The observed in-stent LLL of 0.39 mm
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339for the Combo stent was greater than that reported for
conventional SES, where Cypher (Cordis, Miami Lakes,
Florida) LLL values have been reported up to 0.24 mm,
including diabetic patients (13–15). These angiographic
results are in line with the expected capture of circulating
EPCs by the CD34 antibody, creating a fast and complete
Table 3. Procedural Results
(
Site reported
Device success 1
Lesion success 1
Procedure success (protocol deﬁned) 1
Procedure success (ARC) 1
Number of lesions treated/patient
Number of study stents deployed/patient
Total length of implanted study stents (mm) 1
Maximum diameter of implanted study stents (mm)
QCA
Number of stents implanted/lesion
Final % DS
In-stent
In-segment % DS 1
Acute gain (mm)
In-stent
In-segment
Final TIMI score
TIMI 3 1
Values are n (%) or mean SD.
ARC Academic Research Consortium; CI confidence interval; D
TIMI Thrombolysis In Myocardial Infarction.
Figure 2. Cumulative Frequency Distribution and Histograms of AngiographLLL  late lumen loss.layer of cells leading to the covering of the stent struts.
Experimental data have shown that the abluminal release of
sirolimus by the Combo stent results in a similar effective
dosage in the stented arterial wall, as with the omnidirec-
tional release by the SES, yet with a drastically reduced
release to the circulation (6).
o
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340Angiographic LLL has been used as a surrogate for DES
efficacy in preventing angiographic restenosis and the need
for repeat TLR (16,17). A pooled analysis of 11 randomized
DES trials enrolling 8,726 patients confirmed that LLL is
indeed a suitable surrogate for 12-month TLR rates in
comparing DES with BMS (18). However, given the
logistic curvilinear relationship between LLL and TLR and
the relatively flat curve at LLL values below 0.5 to 0.6 mm,
it seems very unlikely that improvements in LLL translate
into sizable differences in TLR, considering the statistical
power calculation of this trial. Interestingly, the observed
differences in corresponding rates of angiographic restenosis
at 9 months of 5.5% for the Combo stent compared with
9.6% for PES and an incidence of TLR at 12 months of
4.9% for the Combo stent compared with 8.5% for PES
Table 4. Angiographic Results
Combo
(n  109)
Angiographic binary restenosis (%)
In-stent 6 (5.5%)
In-segment 9 (8.3%)
MLD (mm), post-procedure
In-stent 2.69 0.40
In-segment 2.35 0.42
MLD (mm), 9-month follow-up
In-stent 2.31 0.58
In-segment 2.09 0.56
In-stent LLL (mm) 0.39 0.45
In-segment LLL (mm) 0.27 0.46
Values are n (%) or mean SD. Full analysis set: intent-to-treat patien
Late loss estimated by angiographic core laboratory for patients with
CI confidence interval; DS diameter stenosis; LLL late lumen
Figure 3. Gray-Scale and VH IVUS at Baseline and 9-Month Follow-UpIVUS  intravascular ultrasound; VH  virtual histology.did not gain statistical significance but were unexpected,
given the similarity in in-stent LLL. The numerically
lower LLL of the Combo stent seems to be leveraged in
a disproportionally lower TLR rate with Combo in
comparison with PES. This cannot be explained by the
difference between the averages alone but more likely is
the result of the bimodal nature of the LLL distribution
in the PES arm. This bimodal nature indicates a dimin-
ished antiproliferative response to the stent in a particular
patient subgroup and has been reported before for PES
and SES (19).
Furthermore, it has been suggested that in-segment LLL
rather than in-stent LLL might be a better predictor for
clinical events with DES, because edge stenosis at the stent
margins have been found to lead to more TLRs with DES
TAXUS
n  52)
Difference
(95% CI)
Superiority
p Value
5 (9.6%) 4.1% (14.7 to 6.5) 0.34
7 (13.5%) 5.2% (17.3 to 6.9) 0.30
.76 0.31 0.06 (0.18 to 0.05) 0.24
.40 0.36 0.05 (0.17 to 0.08) 0.46
.30 0.56 0.02 (0.17 to 0.21) 0.86
.97 0.57 0.12 (0.06 to 0.31) 0.19
.44 0.56 0.5 (0.21 to 0.11) 0.0012
(Noninferiority p value)
.41 0.54 0.14 (0.30 to 0.02) 0.08
qualifying 9-month angiographic follow-up included in the analyses.
e 9-month qualifying angiogram.
Dminimal lumen diameter.(
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341than with BMS (18). In the REMEDEE trial, the Combo
stent showed a strong trend toward a reduced in-segment
LLL compared with the PES.
Recent data have shown that LLL after DES stent
implantation is increasing over time, resulting in a
continuous increase of TLRs and ST between 1 and 5
years after stenting, seemingly driven by aggressive in-
stent neo-atherosclerosis. The time course of TLR and
ST rates with several DES platforms have clearly shown
that an initial low LLL and TLR rate at 1 year is not
predictive of long-term durability (20 –23). In fact, the
stent with an initially higher TLR (and in-stent LLL)
demonstrates more stable long-term clinical outcome. It
seems that in the long run patients benefit more from an
Table 5. Secondary Effectiveness and Safety Endpoin
Safety and Effectiveness Measures
Com
(n  1
Acute success
Device success 123 (99.
Lesion success 124 (100
Procedure success (protocol deﬁned) 120 (96.
Procedure success (ARC) 114 (91.
Vascular complications 3 (2.4
Measures at 30 days
Death 0 (0.0
Cardiac death 0 (0.0
MI (protocol deﬁned) 3 (2.4
Q-wave 0 (0.0
Non–Q-wave 3 (2.4
MACE (protocol deﬁned) 3 (2.4
ARC stent thrombosis (deﬁnite or probable) 0 (0.0
Clinically driven TLR 0 (0.0
Clinically driven TVR 0 (0.0
Clinically driven TVF (protocol deﬁned) 3 (2.4
Clinically driven TLF (protocol deﬁned) 3 (2.4
Measures at 12 months
Death 2 (1.6
Cardiac death 1 (0.8
MI (protocol deﬁned) 3 (2.4
Q-wave 0 (0.0
Non–Q-wave 3 (2.4
MACE (protocol deﬁned) 11 (8.9
ARC stent thrombosis (deﬁnite or probable) 0 (0.0
Clinically driven TLR 6 (4.9
Clinically driven TVR 8 (6.5
Clinically driven TVF (protocol deﬁned) 13 (10.
Clinically driven TLF (protocol deﬁned) 11 (8.9
Values are n (%) or mean SD. Kaplan-Meier estimates for the rates
ratios and 2-sided 95% CIs for time-to-event variables were obtained
proportions and 2-sided 95% CIs for binary variables were calculated w
MACEmajor adverse cardiac events (composite of death, MI [Q-w
by repeat percutaneous transluminal coronary angioplasty, or CABG)
revascularization; other abbreviations as in Tables 1 and 3.adequately healed stent than from an initially lower LLL. RLong-term follow-up to 5 years in the REMEDEE trial
will provide information as to whether the CD34
antibody-mediated capturing of EPCs combined with the
antiproliferative effect of abluminal sirolimus elution
produces durable clinical results.
IVUS results. Neointimal hyperplasia volume and percent-
ge in-stent volume obstruction measured by gray-scale
VUS showed similar results for the Combo stent and PES.
he observation of neo-atherosclerosis in DES has raised
uestions on the nature of long-term healing and the
arameters that influence it (24). Even though neo-
therosclerosis was also observed in BMS, it seems that its
rogress is more gradual and that the tissue is denser and
ontains less confluent necrotic core than with DES. In the
TAXUS
(n  59)
Difference or
Hazard Ratio (95% CI) p Value
59 (100.0%) 1.01 (0.99–1.02) 1.00
59 (100.0%) N/A N/A
58 (98.3%) 1.02 (0.97–1.06) 1.00
56 (94.9%) 1.03 (0.95–1.12) 0.55
2 (3.4%) 0.71 (0.12–4.16) 0.66
0 (0.0%) N/A N/A
0 (0.0%) N/A N/A
1 (1.7%) 1.44 (0.15–13.83) 0.75
0 (0.0%) N/A N/A
1 (1.7%) 1.44 (0.15–13.83) 0.75
1 (1.7%) 1.44 (0.15–13.83) 0.75
0 (0.0%) N/A N/A
0 (0.0%) N/A N/A
0 (0.0%) N/A N/A
1 (1.7%) 1.44 (0.15–13.83) 0.75
1 (1.7%) 1.44 (0.15–13.83) 0.75
0 (0.0%) N/A 0.33
0 (0.0%) N/A 0.49
1 (1.7%) 1.44 (0.15–13.83) 0.75
0 (0.0%) N/A N/A
1 (1.7%) 1.44 (0.15–13.83) 0.75
6 (10.2%) 0.88 (0.32–2.37) 0.80
0 (0.0%) N/A N/A
5 (8.5%) 0.57 (0.17–1.88) 0.35
6 (10.2%) 0.64 (0.22–1.85) 0.41
7 (11.9%) 0.90 (0.36–2.24) 0.81
6 (10.2%) 0.88 (0.32–2.37) 0.80
ndicated time point are displayed for time-to-event variables. Hazard
ox regression models with treatment as main effect. Differences in
ct methods.
on–Q-wave], emergent CABG, or target lesion revascularization [TLR]
target lesion failure; TVF  target vessel failure; TVR  target vesselts
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342BMS-like composition and morphology of the neointimal
tissue, showing less confluent necrotic core in the Combo
stent in comparison with PES (10). Despite the small
number of patients with VH–IVUS evaluation this obser-
vation was statistically significant, and these observations of
the Combo stent are consistent with the anticipated pro-
healing effect of the immobilized CD34 antibody together
with the time-limited inflammatory aspect of the biode-
gradable polymer, which is resorbed 90 days after implan-
tation, leaving only a BMS after that time (25).
Clinical results. The REMEDEE trial was not powered to
differentiate for clinical endpoints, and very few clinical
events were reported in either group, so it was not surprising
that differences in death, MI, TLR, and their composites
between both groups did not reach statistical significance.
No ARC definite or probable ST was reported for either
device. Long-term follow-up to 5 years will provide results
on very late ST. The absence of a positive HAMA response
after Combo stent implantation suggests that sensitization
by the CD34 antibody is unlikely.
Study limitations. The PES was selected as a control,
ecause at the time of the study design initiation it
epresented a well-accepted first-generation DES that
as been used in other first-in-man studies as a compar-
tor and because its in-stent LLL value was expected to
e in the same range as with Combo, allowing an
ssessment of the primary endpoint with a smaller num-
er of patients.
The REMEDEE trial was powered only for noninferi-
rity of in-stent LLL. Other comparisons between the 2
rms should be interpreted as hypothesis-generating obser-
ations warranting further clinical studies, both with clinical
ndpoints and with suitable surrogate endpoints to demon-
trate the healing effect of the stent. Additionally, the study
opulation was limited to uncomplicated patients with
table angina, undergoing elective PCI.
onclusions
The first-in-man REMEDEE trial with the Combo stent
met the primary objective and found the COMBO stent to
be noninferior to the PES in angiographic in-stent LLL at
9 months. In-stent and in-segment late loss and binary
restenosis rates for the Combo were accordingly low and
comparable to the PES. There was an overall low rate of
clinical events observed in both groups, including no ARC
definite or probable ST. The Combo stent was shown
to be effective and safe throughout the first year in the
REMEDEE trial. Future studies will have to document
long-term safety and efficacy, allowing the attempt for a
reduced duration of DAPT.Reprint requests and correspondence: Dr. Michael Haude,
Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Preus-
senstrasse 84, Neuss 41464, Germany. E-mail: mhaude@
lukasneuss.de.
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APPENDIX
For a detailed listing of the inclusion and exclusion criteria from the study
protocol, please see the online version of this paper.
